Tryp Therapeutics Inc.

CSE: TRYP

Company Logo

Company Overview

Tryp Therapeutics is a clinical stage drug development company led by a management team with extensive drug development experience that is advancing transformative medicines with existing clinical data and known safety profiles for diseases with no effective first-line treatments. The company is building a diversified portfolio of product candidates targeting neuropsychiatric and oncology indications with high unmet medical needs.

Financial Highlights

$0

Revenue (ttm)

$0

Gross Profit (ttm)

-$0.02

Diluted EPS (ttm)

Management Team

Mr. Gregory M. McKee M.B.A., M.A., MBA
Exec. Chairman & CEO

Dr. James P. Gilligan
Pres & Chief Scientific Officer

Mr. Luke Hayes
Chief Financial Officer

Mr. Thomas D'Orazio B.Sc., M.B.A.
Chief Operating Officer

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile

Website

Twitter

Presentation

Key Highlights

Market Capitalization
$28,108,405

Shares Outstanding
60,302,222

Shares Short (% of Float)
118,021 (0%)

Insider Ownership
31%